Neuropsychiatric Complications of Efavirenz in Children With HIV Infection

Hammond, Charles; Eley, Brian; Wilmshurst, Jo M.

doi:10.2217/fvl-2016-0030

Cited by 2 publications

(3 citation statements)

References 76 publications

(183 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, to explain this apparent relationship between EFV and seizure control, one may need to consider the effects EFV has on the central nervous system [23]. Neurotoxic side effects related to EFV are reported but complications of seizures are less frequently noted, especially in children [24]. To date there are 2 published case reports in a 5-year-old South African child and a 45 year old adult with seizures apparently related to use of EFV [25,26].…”

Section: Discussionmentioning

confidence: 99%

“…To date there are 2 published case reports in a 5-year-old South African child and a 45 year old adult with seizures apparently related to use of EFV [25,26]. In the South African setting CYP2B6 G > T mutations are more common, putting children with this at increased risk of toxicity due to subsequent impaired metabolism of EFV [24]. However, screening for this mutation is not routinely available.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Seizures in Children with HIV infection in South Africa: A retrospective case control study

Burman

Wilmshurst

Gebauer

et al. 2019

Seizure

View full text Add to dashboard Cite

A B S T R A C TPurpose: Data relating to the role that Human immunodeficiency virus (HIV) contributes towards seizures in HIV-infected children is limited. The management of seizures in this group is complex due to potential interactions between antiseizure medication and antiretroviral therapies. This study explores the seizure semiology and course of a population of affected children based on questions raised from a previous epidemiological study. Methods: A retrospective case-control study of all patients presenting to an HIV neurology clinic between 2008-2015 was conducted. A multinomial logistic regression model was used to identify risk factors for seizure occurrence in HIV-infected children, as well as factors associated with seizure control. Results: Of 227 HIV-infected children (median 82 months, interquartile range 41-109), 52 (23%) reported a past or present history of seizures. Prior bacterial meningitis (p = 0.03, OR 12.5, 95% CI 1.2-136.1), cerebrovascular accident (CVA, p = 0. 005, OR 8.1, 95% CI 1.9-34.9) and or tuberculous meningitis (TBM, p = 0.0004) was associated with an increased risk of seizures in HIV-infected children. Generalised tonic-clonic seizures were the predominant seizure type (64%) with the majority caused by an infectious aetiology (62%). Thirty-two (62%) of these patients had epilepsy in-line with the latest diagnostic criteria. HIV-infected children with epilepsy who were treated with efavirenz were more likely to have poor seizure control (OR 23.1 95% CI 3.4-159.6, p = 0.0001). Conclusions:This study provides new data highlighting the complex clinical presentation and management challenges of HIV-infected children with seizures.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Seizures in Children with HIV infection in South Africa: A retrospective case control study

Burman

Wilmshurst

Gebauer

et al. 2019

Seizure

View full text Add to dashboard Cite

show abstract

“…Maintaining EFV plasma levels within this window of optimal benefit has proved challenging. Second, the toxicity resulting from high drug levels has been linked to neurological side effects (Van de Wijer et al, 2016), such as dizziness, insomnia, abnormal dreams, anxiety and depression (Arendt, de Nocker, von Giesen, & Nolting, 2007;Dalwadi, Ozuna, Harvey, Viljoen, & Schetz, 2018;Hammond, Eley, & Wilmshurst, 2016). In children, extreme cases have been reported in the literature.…”

mentioning

confidence: 99%

The Pharmacogenetics of Efavirenz Metabolism in Children: The Potential Genetic and Medical Contributions to Child Development in the Context of Long‐Term ARV Treatment

Tan

Bowers

Thuma

et al. 2020

New Directions for Child and Adolescent Development

View full text Add to dashboard Cite

Efavirenz (EFV) is a well‐known, effective anti‐retroviral drug long used in first‐line treatment for children and adults with HIV and HIV/AIDS. Due to its narrow window of effective concentrations, between 1 and 4 μg/mL, and neurological side effects at supratherapeutic levels, several investigations into the pharmacokinetics of the drug and its genetic underpinnings have been carried out, primarily with adult samples. A number of studies, however, have examined the genetic influences on the metabolism of EFV in children. Their primary goal has been to shed light on issues of appropriate pediatric dosing, as well as the manifestation of neurotoxic effects of EFV in some children. Although EFV is currently being phased out of use for the treatment of both adults and children, we share this line of research to highlight an important aspect of medical treatment that is relevant to understanding the development of children diagnosed with HIV.

show abstract

Neuropsychiatric Complications of Efavirenz in Children With HIV Infection

Cited by 2 publications

References 76 publications

Seizures in Children with HIV infection in South Africa: A retrospective case control study

Seizures in Children with HIV infection in South Africa: A retrospective case control study

The Pharmacogenetics of Efavirenz Metabolism in Children: The Potential Genetic and Medical Contributions to Child Development in the Context of Long‐Term ARV Treatment

Contact Info

Product

Resources

About